)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Gufic Biosciences (509079) investor relations material
Gufic Biosciences Q1 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 25/26 earnings summary14 Aug, 2025
Executive summary
Indore facility ramp-up drove operational and financial improvements, with 18–20% capacity utilization in Q1 and a target of 30% by year-end, supporting margin accretion from FY27 onward.
Q1 FY26 revenue reached ₹226.97 crore, up 12% YoY, with EBITDA of ₹33.2 crore and margin of 14.6%.
Product pipeline expanded with 145+ FDA approvals, ongoing tech transfers, and new launches in critical care, reproductive medicine, and aesthetics.
Strong growth in critical care, infertility, aesthetics, and international business segments.
R&D advances in peptides, dual chamber syringes, and immuno-oncology (Selvax) pipeline.
Financial highlights
Q1 FY26 revenue rose to ₹226.97 crore from ₹205 crore in Q1 FY25, mainly due to Indore facility contributions.
EBITDA increased to ₹33.2 crore (Q1 FY26) from ₹27 crore (Q1 FY25); EBITDA margin at 14.6%.
PAT for Q1 FY26 at ₹12.1 crore, down from ₹20.9 crore YoY; PAT margin at 5.3%.
FY25 revenue at ₹819.8 crore, EBITDA ₹140 crore (17.4% margin), PAT ₹69.9 crore.
Cash from operations in FY25 at ₹122.8 crore, with net cash at period end of ₹14.9 crore.
Outlook and guidance
Indore expected to reach breakeven EBITDA at 25% sales utilization; margin improvement anticipated as capacity ramps up and exports increase.
Exports projected to rise to 25% of revenue, with margin expansion expected from FY28 as regulatory approvals and tech transfers progress.
Focus on expanding regulated market presence, scaling CMO, and commercializing pipeline products.
Management targets doubling branded business revenue in 2–3 years and aims for ₹1,000 crore annual revenue as capacity unlocks.
Strategic initiatives to drive growth in botulinum toxin, immuno-oncology, and new drug delivery systems.
When will Indore reach 30% capacity utilization?
Discuss strategy for botulinum toxin international foray.
Elaborate on Sparsh's new distribution methodology.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Gufic Biosciences earnings date
Q2 25/2617 Nov, 2025
Next Gufic Biosciences earnings date
Q2 25/2617 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Gufic Biosciences Limited is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical formulations, active pharmaceutical ingredients (APIs), and herbal products. The company specializes in injectables, lyophilized formulations, antifungals, antibiotics, and critical care medicines, catering to both domestic and international markets. The company is headquartered in Mumbai, India, and its shares are listed on the BSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage